Acyclic nucleoside phosphonate diesters

• US 9,156,867 B2
• Filed: 08/20/2014
• Issued: 10/13/2015
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Hostetler, Karl Y., Beadle, James R., Valiaeva, Nadejda
• Primary Examiner(s): Kifle, Bruck
• Application Number:
  US14/463,908
• Publication Number:
  US 20140364397A1
• Time in Patent Office: 419 Days
• Field of Search: 514/263.38, 514/263.4, 514/274
• US Class Current: 1/1
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07F 9/6512 having the nitrogen atoms in positions 1 and 3
• CPC Class Codes: C07F 9/65583 each of the hetero rings containing nitrogen as ring hetero atom
• CPC Class Codes: C07F 9/6561 containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.

Claims

1. A method for treating a viral infection comprising administering an effective amount of a compound selected from the group consisting of:

2. The method of claim 1, wherein the compound is:

3. The method of claim 1, wherein the compound is:

4. The method of claim 1, wherein the compound is:

5. The method of claim 1, wherein the compound is:

6. The method of claim 1, wherein the compound is:

7. The method of claim 1, wherein the compound is:

8. The method of claim 1, wherein the compound is:

9. The method of claim 1, wherein the compound is:

10. The method of claim 1, wherein the compound is:

11. The method of claim 1, wherein the compound is:

12. The method of claim 1, wherein the compound is:

13. The method of claim 1, wherein the compound is:

14. The method of claim 1, wherein the compound is:

15. The method of claim 1, wherein the compound is:

16. The method of claim 1, wherein the compound is:

17. The method of claim 1, wherein the compound is:

18. The method of claim 1, wherein the viral infection is a human papilloma viral infection selected from the group consisting of HPV 11 infection, HPV 16 infection and HPV 18 infection.

19. The method of claim 18, wherein the compound, or a pharmaceutically acceptable salt thereof, treats a plurality of types of human papilloma virus.

20. The method of claim 18, wherein the human papilloma viral infection is HPV 11 infection.

21. The method of claim 1, wherein the viral infection is human HIV infection.

22. The method of claim 1, wherein the viral infection is hepatitis B viral infection.

23. The method of claim 18, wherein the human papilloma viral infection is HPV 16 infection.

24. The method of claim 18, wherein the human papilloma viral infection is HPV 18 infection.

25. The method of claim 1, wherein the viral infection is vaccinia viral infection.

26. The method of claim 1, wherein the viral infection is an adenovirus infection.

27. The method of claim 1, wherein the viral infection is a cytomegalovirus infection.

28. The method of claim 1, wherein the viral infection is herpes simplex virus 1 infection.

29. The method of claim 1, wherein the viral infection is herpes simplex virus 2 infection.

30. The method of claim 1, wherein the viral infection is BK virus infection.

31. The method of claim 1, wherein the viral infection is JC virus infection.

32. A method for inhibiting growth of a cell transformed by a virus comprising contacting the cell with an effective amount of,

33. A method for treating cancer of the cervix comprising administering an effective amount of